PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
-11.87%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.29B
AUM Growth
+$1.29B
(-17%)
Cap. Flow
-$41.8M
Cap. Flow
% of AUM
-3.23%
Top 10 Holdings %
Top 10 Hldgs %
80.94%
Holding
37
New
–
Increased
7
Reduced
17
Closed
2
Top Buys
| 1 |
SAGE
Sage Therapeutics
SAGE
|
$2.32M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
$1.48M |
| 3 |
Karyopharm Therapeutics
KPTI
|
$1.11M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$962K |
| 5 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$903K |
Top Sells
| 1 |
ABMD
Abiomed Inc
ABMD
|
$8.16M |
| 2 |
United Therapeutics
UTHR
|
$6.12M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$5.65M |
| 4 |
Biogen
BIIB
|
$5.06M |
| 5 |
Align Technology
ALGN
|
$4.84M |
Sector Composition
| 1 | Healthcare | 98.39% |
| 2 | Financials | 1.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$11.2B
| $165M | 12.75% | 2,139,614 -73,336 | -3% | -$5.65M |
|
|
ABMD
2
DELISTED
Abiomed Inc
ABMD
| $164M | 12.66% | 494,397 -24,636 | -5% | -$8.16M |
|
3
Insmed
INSM
$28.8B
| $138M | 10.69% | 5,881,299 -144,407 | -2% | -$3.39M |
|
|
4
United Therapeutics
UTHR
$13.8B
| $117M | 9.06% | 653,079 -34,127 | -5% | -$6.12M |
|
5
Amicus Therapeutics
FOLD
$2.34B
| $93.8M | 7.25% | 9,903,761 -210,282 | -2% | -$1.99M |
|
6
STAAR Surgical
STAA
$1.36B
| $90.9M | 7.02% | 1,136,968 -3,543 | -0.3% | -$283K |
|
|
RVNC
7
DELISTED
Revance Therapeutics, Inc.
RVNC
| $86.1M | 6.66% | 4,415,689 +46,323 | +1% | +$903K |
|
|
8
Biogen
BIIB
$19.4B
| $76M | 5.88% | 360,981 -24,019 | -6% | -$5.06M |
|
9
Prothena Corp
PRTA
$441M
| $61.5M | 4.75% | 1,681,477 -3,805 | -0.2% | -$139K |
|
10
Acadia Pharmaceuticals
ACAD
$4.38B
| $54.5M | 4.22% | 2,251,834 -86,043 | -4% | -$2.08M |
|
|
11
Karyopharm Therapeutics
KPTI
$61.7M
| $41.4M | 3.2% | 5,621,533 +151,081 | +3% | +$1.11M |
|
|
SAGE
12
DELISTED
Sage Therapeutics
SAGE
| $28.2M | 2.18% | 851,719 +69,989 | +9% | +$2.32M |
|
13
Vanda Pharmaceuticals
VNDA
$279M
| $28.2M | 2.18% | 2,491,200 -343,044 | -12% | -$3.88M |
|
14
eHealth
EHTH
$118M
| $20.5M | 1.59% | 1,652,260 +36,690 | +2% | +$455K |
|
|
15
Align Technology
ALGN
$10.3B
| $19.3M | 1.49% | 44,305 -11,100 | -20% | -$4.84M |
|
16
Alkermes
ALKS
$4.78B
| $17.7M | 1.37% | 673,571 -80,629 | -11% | -$2.12M |
|
17
Gossamer Bio
GOSS
$562M
| $15.2M | 1.18% | 1,756,757 -16,193 | -0.9% | -$141K |
|
18
Kezar Life Sciences
KZR
$28.9M
| $10.9M | 0.84% | 656,200 | – | – |
|
19
AnaptysBio
ANAB
$569M
| $10.7M | 0.82% | 431,024 -5,568 | -1% | -$138K |
|
20
Syndax Pharmaceuticals
SNDX
$1.41B
| $10.6M | 0.82% | 612,600 +13,700 | +2% | +$238K |
|
|
GRTS
21
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $9.6M | 0.74% | 2,330,504 -25,778 | -1% | -$106K |
|
|
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
| $9.04M | 0.7% | 4,473,967 +476,141 | +12% | +$962K |
|
|
EPZM
23
DELISTED
Epizyme, Inc
EPZM
| $7.79M | 0.6% | 6,774,541 +1,289,328 | +24% | +$1.48M |
|
24
Travere Therapeutics
TVTX
$1.56B
| $4.28M | 0.33% | 166,069 | – | – |
|
25
Cytokinetics
CYTK
$4.23B
| $4.11M | 0.32% | 111,717 -11,969 | -10% | -$441K |
|